Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0T3CE
|
||||
Former ID |
DIB016439
|
||||
Drug Name |
SUPER-LEU-DOX
|
||||
Synonyms |
CPI-0004; CPI-0004Na; CPI-004Na; DTS-201; TAP-doxorubicin; TSP-doxorubicin; Phthacene-5,12-dione sodium salt; N-[N-(3-Carboxypropionyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucyl]daunorubicin sodium salt; (8S,10S)-10-[3-[N-(3-Carboxy-1-oxopropyl)-beta-alanyl-L-leucyl-L-alanyl-L-leucylamido]-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy]-8-(hydroxyacetyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrona
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Discontinued in Phase 2 | [546627] | ||
Company |
Diatos SA
|
||||
CAS Number |
CAS 274912-87-7
|
||||
Target and Pathway | |||||
Target(s) | DNA topoisomerase II | Target Info | Modulator | [1572591] | |
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.